| Nov 15 |
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Ascendis Pharma GAAP EPS of -€1.72, revenue of €57.83M
|
| Nov 14 |
Ascendis Pharma Reports Third Quarter 2024 Financial Results
|
| Nov 14 |
(ASND) - Analyzing Ascendis Pharma's Short Interest
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
Ascendis Pharma Q3 2024 Earnings Preview
|
| Nov 7 |
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
|
| Nov 6 |
High Growth Tech Stocks In The United States To Watch
|
| Nov 5 |
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
|
| Nov 5 |
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
|
